Biodistribution of [68Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions

Abstract

This biodistribution study provided a broad range of uptake data of [(68)Ga]PSMA-11 for normal organs/tissues, primary prostate tumours and metastatic lesions based on a large patient cohort. Both PT and small metastatic lesions were detectable due to their high tracer uptake. Four-times-higher median uptake in PT in comparison to normal prostate stroma resulted in a high diagnostic accuracy that could potentially be used for multimodal image-guided biopsy with dedicated reconstruction software.

Use of gallium‐68 prostate‐specific membrane antigen positron‐emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature

“…This is confirmed by the high efficacy of salvage radiotherapy (SRT) to the prostatic fossa in patients with a negative 68 Ga-PSMA PET result [36]. Failure to detect local recurrence is probably attributable to the inability to distinguish tumour activity from intense activity in the nearby bladder owing to urinary radiotracer excretion and to the fact that less aggressive PCa more often returns locally and less aggressive disease expresses less PSMA [46][47][48][49].…”

“…Most studies report a perpatient specificity of 90% or higher [10,11,13,[15][16][17]19]. This high specificity is a result of the high expression of PSMA in PCa and lymph node metastases, resulting in a high tumour to background ratio [46][47][48][49].…”

68Ga‐PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature

“…The number of patients ranged from 7 to 17 with a total of 51 patients investigated for staging purposes (Demirkol et al, 2015;Prasad et al, 2016;Sahlmann et al, 2016;Sterzing et al, 2016). The number of patients ranged from 7 to 17 with a total of 51 patients investigated for staging purposes (Demirkol et al, 2015;Prasad et al, 2016;Sahlmann et al, 2016;Sterzing et al, 2016).…”

“…Four papers that examined patients for staging purposes were identified, of which three papers included patients with different stages of prostate cancer. The number of patients ranged from 7 to 17 with a total of 51 patients investigated for staging purposes (Demirkol et al, 2015;Prasad et al, 2016;Sahlmann et al, 2016;Sterzing et al, 2016). In an additional three papers, the use of 68 Ga-PSMA PET/CT in different stages of prostate cancer was investigated, but the outcome in patients at the time of staging was not reported separately (Afshar-Oromieh et al, 2015a;Hijazi et al, 2015Hijazi et al, , 2016.…”

Invited Commentary

“…The normal biodistribution of 68 Ga-DOTA-TATE is similar to that of 111 In-DTPA-octreotide and other 68 Ga-DOTA conjugates and allows visualization of the liver, spleen, pituitary gland, thyroid gland, kidneys, adrenal and salivary glands, stomach, and bowel (12). The pancreas shows variable uptake.…”